Evolocumab effectiveness in the real-world setting: Austrian data from the pan-European observational HEYMANS study.

ABSTRACT:

Background

This real-world study examined clinical characteristics and dyslipidemia management among patients initiating evolocumab across 12 European countries. Austrian data are reported.

Methods

Data of consenting adults were collected for ≤ 6 months prior to evolocumab initiation (baseline) and ≤ 30 months post-initiation. Patient characteristics, lipid lowering therapy (LLT, i.e. statin and/or ezetimibe) and lipid values were collected from medical records.

Results

In Austria, 363 patients were enrolled. At baseline, 52% of patients initiated evolocumab without background LLT; the median (Q1, Q3) initial low-density lipoprotein cholesterol (LDL-C) level was 142 (111, 187) mg/dL. Within 3 months of evolocumab treatment, median LDL‑C decreased by 59% to 58 (37, 91)

SUBMITTER: Ebenbichler C 

PROVIDER: S-EPMC10837260 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature